No abstract available.
Blood Glucose* ; Glucose*

No abstract available.
Blood Glucose* ; Glucose*

BACKGROUND: In diabetic patients, both glucose and hemoglobin A1c (HbA1c) concentrations are frequently measured to monitor glycemic control. We examined the analytical performance of the recently developed, automated, ADAMS bridge system (Arkray, Inc., Japan) consisting of the ADAMS glucose GA-1171 and the ADAMS HbA1c HA-8180 analyzers, which allows the consecutive measurement of glucose and HbA1c concentrations. METHODS: We evaluated precision, linearity, carry-over, effects of hematocrit, and turnaround time. Method comparison was conducted between GA-1171 and UniCel DxC 800 (Beckman Coulter, Inc., USA) and Synchron CX3 Delta (Beckman Coulter) for glucose, and between HA-8180 and HLC-723 G8 (Tosoh Bioscience, Inc., Japan) for HbA1c measurements. RESULTS: Total precision (% CV) in measuring high and low level controls was 1.11% and 1.21% for glucose using GA-1171, and 0.86% and 1.3% for HbA1c using HA-8180, respectively. In the linearity test, R2 was 0.9997, 0.9991 and 0.9973 when measuring plasma glucose (58-532 mg/dL), whole blood glucose (74-401 mg/dL), and HbA1c concentrations (4.7-14.7%), respectively. Good correlation was observed between GA-1171 and DxC 800 (r=0.9987), and between HA-8180 and HLC-723 G8 (r=0.9980). Carry-over effect was less than 0.5% for glucose and HbA1c. Turnaround time was reduced from 7 min (CX3 Delta) and 1.43 min (HLC-723 G8) to 2.16 min (GA-1171) and 1.54 min (HA-8180), respectively, when whole blood glucose and HbA1c concentrations were measured consecutively by the ADAMS bridge system. CONCLUSIONS: The ADAMS bridge system had a simple operating procedure and showed an adequate performance and a rapid turnaround time.
Blood Glucose ; Glucose* ; Hematocrit ; Humans

Study on 50 patients (male: 12, female: 38), between the ages of 72 and 40, with hypertension (62% of patients), obesity (60%) in which abdominal obesity (78%) was carried out in Bach Mai Hospital during July 2000- March 2001. The results found that the lipemia disorder frequently occurred in patients with reduced glucose toleration according to the classification of Fredrichson (type IV). 69% patients with the reduced glucose toleration had a lipemia disorder accompanying with hypertension. The risk of hypertension among these patients was higher 6.7 times than this among patients without the lipemia disorder. 93% patients with the reduced glucose toleration and obesity had a lipemia disorder. This rate in the patients with abnormal obesity was 97%; 100% of patients with the reduced glucose toleration had signs of coronary insufficiency
Glucose ; Lipoprotein Lipase ; Blood Glucose

BACKGROUND: Subjects with normal glucose tolerance (NGT) who have a high 1-hour postload plasma glucose level (> or =155 mg/dL; NGT 1 hour-high) have been shown to be at higher risk for type 2 diabetes than subjects with NGT 1 hour-low postload plasma glucose level (<155 mg/dL). We compared beta-cell function in subjects with NGT 1 hour-high, NGT 1 hour-low, and impaired glucose tolerance (IGT). METHODS: We classified subjects into NGT 1 hour-low (n=149), NGT 1 hour-high (n=43), and IGT (n=52). The beta-cell function was assessed based on insulinogenic index (IGI), oral disposition index (DI), and insulin secretion-sensitivity index-2 (ISSI-2). RESULTS: Insulin sensitivity was comparable between the subjects with NGT 1 hour-high and NGT 1 hour-low. The beta-cell function with/without adjusting insulin sensitivity was significantly different among the three groups. The IGI (pmol/mmol) was 116.8+/-107.3 vs. 64.8+/-47.8 vs. 65.8+/-80.6 (P=0.141), oral DI was 3.5+/-4.2 vs. 1.8+/-1.4 vs. 1.8+/-3.1 (P<0.001), and ISSI-2 was 301.2+/-113.7 vs. 213.2+/-67.3 vs. 172.5+/-87.5 (P<0.001) in NGT 1 hour-low, NGT 1 hour-high, and IGT, respectively. Post hoc analyses revealed that oral DI and ISSI-2 were significantly different between NGT 1 hour-low and NGT 1 hour-high but comparable between NGT 1 hour-high and IGT. CONCLUSION: Among Korean subjects with NGT, those who have a higher 1-hour postload glucose level have a compromised insulin-sensitivity adjusted beta-cell function to a similar degree as IGT subjects.
Blood Glucose* ; Glucose Tolerance Test ; Glucose* ; Insulin ; Insulin Resistance

On department of anesthesiology, Hanyang university hospital, we used to the Diascan-S for portable blood glucose monitoring during surgery with anesthesia. So, we try to know about the accuracy, the precision and the specificity of that instrument. Period to check for blood glucose was devided to 3 groups that are on just after induction, the operation of main lesion, the end of surgery and we compared to the blood glucose level by the Diascan-S and the standard reference test. Central laboratory used glucose oxidase method to check blood glueose as the standard reference test. Thereafter we got the conclusions as follow. 1) We had got to good correlation between the blood glucose level by Diascan-S and the stan-dard reference test. (Y=65+0.64X, correlation coefficiency 0.58, p value; 0.0000) 2) When the blood glucose levels had devided as below from l00 mg/dl, 100 mg/dl to 150 mg/ dl and above 150 mg/dl, we only got to good correlation blood glocose level by Diascan-S and the standard reference test from 100 mg/dl to l50 mg/dl. (Y=11+2.5X, correlation coefficieny ; 0.51, p value ; 0.0000) 3) When we had tested for blood glucose on ]ust after anesthesia induction and the operation on main lesion, the end of surgery, the results of each period have a good correation each other by Diascan-S and the standard reference test. (a) Just after anesthesia induction Y = 51+0.50X, correlation coefficiency 0.52, p value 0.0000 (b) Operation for main lesion Y = 80+0.38X, correlation coefficiency 0.45, p value 0.0000 (c) End of surgery Y = 61+0.54X, correlation coefficiency ; 0.62, p value 0.0000 4) The condition of instrument had devided to two conditions of Diascan-S as was calibrated by technician reqularly or not, got to more confident correlation coefficiency when the Diascan-S had calibrated by technician reqularly. (a) had calibrated reqularly Y = 40+0.62X, correlation coefficiency 0.65, p value: 0.0000 (b) had not calibration Y = 77+0.42X, correlation coefficiency ; 0.36, p value: 0.0026 By above results, we got conclusions that portable glucose monitoring instrument(Diascan-s) can use to know to change of blood sugar during anesthesia. And then, if we got the result of blood glucose level as belows 100 mg/dl or above 150 mg/dl when used Diascan-S, should try to test again and must compared to standard reference test of central laboratory. Diascan-S must be ca)ibrated by technician reqularly if we try to get more accurate results of blood glucose by Diascan-S.
Anesthesia ; Anesthesiology ; Blood Glucose* ; Calibration ; Glucose Oxidase* ; Glucose* ; Sensitivity and Specificity

BACKGROUND: Self-monitoring blood glucose devices are widely used for self-monitoring and point-of-care testing (POCT) in the management of diabetic patients. We performed the present study to evaluate the performance of Precision Q.I.DR Blood Glucose Testing System using electochemical detection techique. METHODS: Precision Q.I.DR was evaluated for linearity, precision, comparison of method, and the effect of sample volume, hematocrit concentration, reapplication, operator, and application methods. RESULTS: Precision Q.I.DR revealed good linearity in glucose concentration ranging from 40 mg/dL to 550 mg/dL (r2=0.9874). In the precision study, within-run and total-run CVs were within 10%. Excellent correlation was found between Precision Q.I.DR and Hitachi 7070 (y = 1.0332 x, r = 0.9195). Sample volume, reapplication, operator, and application method did not produce significant effect on the test result. Over- or underestimation of glucose values was found with the change of hematocrit concentration. CONCLUSIONS: Precision Q.I.DR showed good linearity, precision, and correlation with reference method. No significant effect of testing procedure or operator was found. Precision Q.I.DR provided rapid and reliable result of blood glucose and seems appropriate for clinical use in the management of diabetic patients.
Blood Glucose ; Diabetes Mellitus ; Glucose* ; Hematocrit ; Humans

No abstract available.
Blood Glucose* ; Glucose* ; Humans ; Infant, Newborn*

BACKGROUND: Glucometer is a most widely-used point-of-care testing (POCT) analyzer and plays an important role in diabetes management. We evaluated the performance of the recently developed glucometer, COSMOsensor (Cosmogenome Inc., Seoul, Korea), comparing it with three foreign-made glucometers. METHODS: COSMOsensor was evaluated for linearity, precision, comparison of method and analysing time as well as the effect of operator. Other glucometers, Accu-Chek inform (Roche Diagnostics LTD., Mannheim, Germany), Precision(TM)PCx (Abbott Laboratories, Bedford, MA, USA), and Sure- Step.Flexx (LifeScan Inc., Milpitas, CA, USA) were evaluated for the same categories according to NCCLS guidelines. RESULTS: All four glucometers showed a good linearity (r> or =0.9814) and the within-run and total-run coefficients of variation (CVs) were within 3.5%. A high correlation (r> or =0.9659) was also found between the glucometers and Hitachi 7600 (Hitachi Co., Tokyo, Japan) in the central laboratory. Although differences with the reference method were within an allowable range, all glucometers showed variable bias compared with the reference method. CONCLUSIONS: The COSMOsensor showed a good analytical performance in linearity, precision, and correlation with the reference method, when compared with other foreign-made glucometers. Its rapid turnaround time and easy operation are appropriate for diabetes management and a rapid POCT analyzer. All glucometers showed variable biases, which might be due to different calibration status.
Bias (Epidemiology) ; Blood Glucose ; Calibration ; Glucose* ; Seoul

BACKGROUND: Glucometers are widely used for self-monitoring and point-of-care testing in diabetes management. We evaluated the performance of the recently developed Wisecheck Glucose Monitoring System (Wisemeditech, Korea) compared to that of 2 other well-known glucometer systems. METHODS: The Wisecheck glucometer was evaluated for precision, linearity, and carryover rate. One-hundred fifty samples samples were tested, and the results obtained from the Wisecheck glucometer, ACCU-CHEK Performa (Roche Diagnostics, Germany) and SD GlucoLink (SD Diagnostics, Korea) were compared to those obtained using the laboratory reference method from the Toshiba 200FR (Toshiba, Japan), according to the Clinical and Laboratory Standards Institute (CLSI) guidelines. RESULTS: The coefficient of variation (CV) values for within-run imprecision at low, middle, and high levels were 2.06%, 1.02%, and 2.02%, respectively, and the CV values for total-run imprecision at low, middle, and high levels were 2.98%, 2.41%, and 1.88%, respectively. In the linearity test, the coefficient of determination (R2) was 0.9985 in glucose concentration ranging from 48.6 mg/dL to 428 mg/dL (P<0.0001). The results obtained using the Wisecheck glucometer were well correlated with those obtained using the Toshiba 200FR (R2=0.980, P<0.0001). The carryover rate was 0.12%. CONCLUSIONS: The Wisecheck glucometer showed good precision, linearity, and correlation with the reference method. It provided rapid and reliable measurements of blood glucose levels and seemed appropriate for use in diabetes management.
Blood Glucose ; Diabetes Mellitus ; Glucose* ; Methods